Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were assessed in patients with type 2 diabetes who had inadequate glycemic control (HbA1c [A1C] ≥7 and ≤10%) with metformin alone. RESEARCH DESIGN AND METHODS—After a screening diet/exercise run-in period, a metformin dose titration/stabilization period, and a 2-week, single-blind, placebo run-in period, 701 patients, aged 19–78 years, with mild to moderate hyperglycemia (mean A1C 8.0%) receiving ongoing metformin (≥1,500 mg/day) were randomly assigned to receive the addition of placebo or sitagliptin 100 mg once-daily in a 1:2 ratio for 24 weeks. Patients exceeding specific glycemic limits were provided rescue therapy (pioglitazone) until the end of the study. The efficacy analyses were based on an all-patients-treated population using an ANCOVA and excluded data obtained after glycemic rescue. RESULTS—At week 24, sitagliptin treatment led to significant reductions compared with placebo in A1C (−0.65%), fasting plasma glucose, and 2-h postmeal glucose. Fasting insulin, fasting C-peptide, fasting proinsulin-to-insulin ratio, postmeal insulin and C-peptide areas under the curve (AUCs), postmeal insulin AUC–to–glucose AUC ratio, homeostasis model assessment of β-cell function, and quantitative insulin sensitivity check index were significantly improved with sitagliptin relative to placebo. A significantly greater proportion of patients achieved an A1C <7% with sitagliptin (47.0%) than with placebo (18.3%). There was no increased risk of hypoglycemia or gastrointestinal adverse experiences with sitagliptin compared with placebo. Body weight decreased similarly with sitagliptin and placebo. CONCLUSIONS—Sitagliptin 100 mg once-daily added to ongoing metformin therapy was efficacious and well tolerated in patients with type 2 diabetes who had inadequate glycemic control with metformin alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, studies report an increased incidence of nasopharyngitis in subjects randomly assigned to DPPIV inhibitor 35,38,40 ; in 1 study, 1 of 175 sitagliptin-treated subjects was hospitalized for angioedema.41”
From Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema (2008) · cites this paper as [40]
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s33 · Cited by 609
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
Herman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Pospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
Cited by
Items 101–200 of 785
Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug
IDRIS, I. R., & Donnelly, R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00705.x · Cited by 124
Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D'Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 109
Incretin-Based Therapies: Review of Current Clinical Trial Data
Peters, A. L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.007 · Cited by 119
Sifri, S. A., Basiounny, A., Echtay, A. S., Omari, M. A., Harman‐Boehm, I., KADDAHA, G., Tayeb, K., Mahfouz, A., Elq, A. H. A., Radican, L., et al. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02797.x · Cited by 116
Self-citationSitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Plosker, G. L. (2014) · Drugs · doi:10.1007/s40265-013-0169-1 · Cited by 117
Monami, M., Dicembrini, I., & Mannucci, E. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12176 · Cited by 101
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis
Park, H., Park, C., Kim, Y., & Rascati, K. L. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r041 · Cited by 99
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
Engel, S. S., Golm, G. T., Shapiro, D., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-3 · Cited by 100
Monami, M., Vitale, V., Ambrosio, M. L., Bartoli, N., Toffanello, G., Ragghianti, B., Monami, F., Marchionni, N., & Mannucci, E. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0045-5 · Cited by 108
Yang, W., Pan, C. Y., Tou, C., Zhao, J., & Gause‐Nilsson, I. A. M. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.07.035 · Cited by 103
GLP‐1: physiological effects and potential therapeutic applications
Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00853.x · Cited by 95
Esposito, K., Cozzolino, D., Bellastella, G., Maiorino, M. I., Chiodini, P., Ceriello, A., & Giugliano, D. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01380.x · Cited by 95
Fouqueray, P., Pīrāgs, V., Inzucchi, S. E., Bailey, C. J., Schernthaner, G., Diamant, M., & Lebovitz, H. E. (2012) · Diabetes Care · doi:10.2337/dc12-0453 · Cited by 96
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
Gallwitz, B. (2007) · Vascular Health and Risk Management · doi:10.2147/vhrm.2007.3.2.203 · Cited by 110
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes
Åhrén, B. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802584126 · Cited by 102
Madsbad, S., Krarup, T., Deacon, C. F., & Holst, J. J. (2008) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328302f414 · Cited by 93
Sitagliptin phosphate: A DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
Zerilli, T., & Pyon, E. Y. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.12.034 · Cited by 104
Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus
Jellinger, P. S., Davidson, J. A., Blonde, L., EINHORN, D. F., Grunberger, G., Handelsman, Y., Hellman, R., Lebovitz, H. E., Levy, P., & Roberts, V. L. (2007) · Endocrine Practice · doi:10.4158/ep.13.3.260 · Cited by 104
Mechanisms by which cocoa flavanols improve metabolic syndrome and related disorders
Strat, K. M., Rowley, T. J., Smithson, A. T., Tessem, J. S., Hulver, M. W., Liu, D., Davy, B. M., Davy, K. P., & Neilson, A. P. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.12.008 · Cited by 101
Strom Halden, T. A., Asberg, A., Vik, K., Hartmann, A., & Jenssen, T. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft536 · Cited by 89
Xu, L., Man, C. D., Charbonnel, B., Meninger, G., Davies, M. J., Williams‐Herman, D., Cobelli, C., & Stein, P. P. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00887.x · Cited by 88
Self-citationDiabetes and obesity: therapeutic targeting and risk reduction – a complex interplay
Niswender, K. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01175.x · Cited by 87
Ji, L., Han, P., Liu, Y., Yang, G., Dieu Van, N. K., Vijapurkar, U., Qiu, R., & Meininger, G. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12385 · Cited by 86
Self-citationPi-Sunyer, F. X. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2056 · Cited by 86
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes
Flatt, P. R. (2008) · Frontiers in bioscience · doi:10.2741/2956 · Cited by 89
The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors
Filippatos, T. D., Athyros, V. G., & Elisaf, M. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.907274 · Cited by 91
Rizzo, M., Rizvi, A. A., Spinas, G. A., Rini, G. B., & Berneis, K. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903241633 · Cited by 83
DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
Deacon, C. (2008) · Frontiers in Bioscience · doi:10.2741/2799 · Cited by 80
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
Ahren, B. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1944 · Cited by 83
DPP4 Inhibitors: a new approach in diabetes treatment
Doupis, J., & Veves, A. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0076-1 · Cited by 94
Reducing Cardiovascular Complications of Type 2 Diabetes by Targeting Multiple Risk Factors
Reasner, C. A. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31817ffe5a · Cited by 84
Lyseng-Williamson, K. A. (2007) · Drugs · doi:10.2165/00003495-200767040-00007 · Cited by 97
Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes
Hollander, P. (2007) · Diabetes Spectrum · doi:10.2337/diaspect.20.3.159 · Cited by 80
Fouqueray, P., Pīrāgs, V., Diamant, M., Schernthaner, G., Lebovitz, H. E., Inzucchi, S. E., & Bailey, C. J. (2014) · Diabetes Care · doi:10.2337/dc13-2349 · Cited by 83
Schwarz, B., Gouveia, M. R. D. A., Chen, J., Nocea, G., Jameson, K., Cook, J., Krishnarajah, G., Alemao, E., Yin, D., & Sintonen, H. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00886.x · Cited by 84
Managing diabetes in hemodialysis patients: Observations and recommendations
Shrishrimal, K., Hart, P., & Michota, F. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76a.09054 · Cited by 78
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Deacon, C. F., & Holst, J. J. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0030-9 · Cited by 88
Zambrowicz, B., Ding, Z., Ogbaa, I., Frazier, K., Banks, P. L., Turnage, A., Freiman, J. P., Smith, M. G., Ruff, D. A., Sands, A., et al. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.01.010 · Cited by 84
Hong, E. S., Khang, A. R., Yoon, J. W., Kang, S. M., Choi, S. H., Park, K. S., Jang, H. C., Shin, H., Walford, G. A., & Lim, S. K. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01600.x · Cited by 81
Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes
Barnett, A. H., Cradock, S., Fisher, M., Hall, G., Hughes, E., & Middleton, A. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02332.x · Cited by 77
Aso, Y., Ozeki, N., Terasawa, T., Naruse, R., Hara, K., Suetsugu, M., Takebayashi, K., Shibazaki, M., Haruki, K., Morita, K., et al. (2011) · Translational research · doi:10.1016/j.trsl.2011.09.005 · Cited by 83
Advances in therapy for type 2 diabetes: GLP–1 receptor agonists and DPP–4 inhibitors
Kennedy, L., & Davidson, J. A. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.05 · Cited by 75
Recent advances in incretin‐based therapies
Russell-Jones, D. L., & Gough, S. C. L. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04483.x · Cited by 82
Efficacy and safety of incretin-based therapies: Clinical trial data
White, J. R. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09079 · Cited by 79
Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus
Rosenstock, J., & Zinman, B. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3280a02f65 · Cited by 78
van Genugten, R. E., van Raalte, D. H., & Diamant, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01473.x · Cited by 73
DPP‐4 inhibitors and risk of infections: a meta‐analysis of randomized controlled trials
Yang, W., Cai, X., Han, X., & Ji, L. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2723 · Cited by 77
Kongwatcharapong, J., Dilokthornsakul, P., Nathisuwan, S., Phrommintikul, A., & Chaiyakunapruk, N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.146 · Cited by 72
Emerging treatment options for type 2 diabetes
Piya, M. K., Tahrani, A. A., & Barnett, A. H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03711.x · Cited by 72
New Approaches to Treating Type 2 Diabetes Mellitus in the Elderly: Role of Incretin Therapies
Abbatecola, A. M., Maggi, S., & Paolisso, G. (2008) · Drugs & Aging · doi:10.2165/0002512-200825110-00002 · Cited by 73
Recent advances in the management of type 2 diabetes mellitus: a review
Srinivasan, B. T., Jarvis, J., Khunti, K., & Davies, M. J. (2008) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.067918 · Cited by 77
Fibroblast activation protein and chronic liver disease
Wang, X. M., Yao, T.-W., Nadvi, N. A., Osborne, B., McCaughan, G. W., & Gorrell, M. D. (2007) · Frontiers in bioscience · doi:10.2741/2918 · Cited by 73
Drucker, D. J., Easley, C., & Kirkpatrick, P. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2245 · Cited by 76
Monami, M., Cremasco, F., Lamanna, C., Marchionni, N., & Mannucci, E. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1184 · Cited by 69
Dipeptidyl Peptidase IV Inhibitors and the Incretin System in Type 2 Diabetes Mellitus
Langley, A., Suffoletta, T. J., & Jennings, H. R. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.8.1163 · Cited by 67
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update)
Gallwitz, B. (2007) · Drugs of Today · doi:10.1358/dot.2007.43.11.1157620 · Cited by 66
Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?
Zinman, B. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.003 · Cited by 70
Derosa, G., Carbone, A., Franzetti, I., Querci, F., Fogari, E., Bianchi, L., Bonaventura, A., Romano, D., Cicero, A. F. G., & Maffioli, P. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.05.022 · Cited by 77
Yang, W., Guan, Y., Shentu, Y., Li, Z., Johnson‐Levonas, A. O., Engel, S. S., Kaufman, K. D., Goldstein, B. J., & Alba, M. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2012.00213.x · Cited by 75
Fu, J., Zhu, J., Hao, Y.-H., Guo, C., & Zhou, Z. (2016) · Scientific Reports · doi:10.1038/srep29104 · Cited by 67
Min, H. S., Kim, J. E., Lee, M., Song, H. K., Kang, Y. S., Lee, M. J., Lee, J. E., Kim, H. W., Cha, J. J., Chung, Y. Y., et al. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.50 · Cited by 67
Varney, J. E., Weiland, T. J., Inder, W. J., & Jelinek, G. A. (2014) · Internal Medicine Journal · doi:10.1111/imj.12515 · Cited by 63
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus
Kennedy, L., & Freeman, J. S. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.03 · Cited by 63
Mikhail, N. E. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.845 · Cited by 66
Cohen, A., & Horton, E. S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182068 · Cited by 62
Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
Silva Júnior, W. S. D., Godoy-Matos, A. F. D., & Kraemer-Aguiar, L. G. (2015) · BioMed Research International · doi:10.1155/2015/816164 · Cited by 61
Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions
Holstein, A., & Beil, W. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902806424 · Cited by 61
Cefalu, W. T., Buse, J. B., Del Prato, S., Home, P. D., LeRoith, D., Nauck, M. A., Raz, I., Rosenstock, J., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-1395 · Cited by 61
Verma, S., Goldenberg, R. M., Bhatt, D. L., Farkouh, M. E., Quan, A., Teoh, H., Connelly, K. A., Leiter, L. A., & Friedrich, J. O. (2017) · CMAJ Open · doi:10.9778/cmajo.20160058 · Cited by 61
Ashish, K., Akash, S., Rita, K. S., Kunal, K., Divya, S., Srinivasan, B. P., Ashok, S., Santosh, K., Gaur, S., Vijay, S., et al. (2012) · Journal of Biomedical Research · doi:10.7555/jbr.26.20110054 · Cited by 62
Lukashevich, V., Del Prato, S., Araga, M., & Kothny, W. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12229 · Cited by 59
Davies, M., Pratley, R., Hammer, M., Thomsen, A. B., & Cuddihy, R. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03074.x · Cited by 60
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
Kim, S., Yoo, J.-H., Lee, W. J., & Park, C. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.5.339 · Cited by 62
Dipeptidyl peptidase iv inhibitors and diabetes therapy
McIntosh, C. H. S. (2007) · Frontiers in bioscience · doi:10.2741/2797 · Cited by 62
Stonehouse, A. H., Darsow, T., & Maggs, D. G. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00143.x · Cited by 69
Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus
Kania, D. S., Gonzalvo, J. D., & Weber, Z. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.06.016 · Cited by 61
Kendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.009 · Cited by 69
Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors
Hollander, P. A., & Kushner, P. R. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2144 · Cited by 60
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes
Deacon, C. F. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.4.533 · Cited by 59
Vergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.07.001 · Cited by 58
Graefe-Mody, E. U., Padula, S. J., Ring, A., Withopf, B., & Dugi, K. A. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903094361 · Cited by 63
Berg, J. K., Shenouda, S. K., Heilmann, C. R., Gray, A. L., & Holcombe, J. H. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01428.x · Cited by 57
Barnett, A., Allsworth, J., Jameson, K., & Mann, R. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x199691 · Cited by 57
Pratley, R. E., Fleck, P. R., & Wilson, C. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12258 · Cited by 56
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin
Åhrén, B., Foley, J. E., & Bosi, E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01321.x · Cited by 64
Sitagliptin: A Novel Drug for the Treatment of Type 2 Diabetes
Choy, M., & Lam, S. (2007) · Cardiology in Review · doi:10.1097/crd.0b013e318123f771 · Cited by 73
Complications of Diabetes Therapy
Corathers, S. D., Peavie, S., & Salehi, M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.005 · Cited by 65
Scheen, A. J. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.01.002 · Cited by 69
Incretin agents in type 2 diabetes.
Ross, S. A., & Ékoé, J.-M. (2010) · PubMed · Cited by 59
Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Gilbert, M. P., & Pratley, R. E. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.013 · Cited by 58
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes
Ahrén, B. (2014) · World J Diabetes · doi:10.4239/wjd.v5.i1.40 · Cited by 51
Pratley, R. E. (2008) · PubMed · Cited by 56
Early therapy for type 2 diabetes in China
Yang, W., & Weng, J. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70136-6 · Cited by 57
Neumiller, J. J. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.013 · Cited by 59
Yoon, K., Shockey, G., Teng, R., Golm, G. T., Thakkar, P., Meehan, A. G., Williams‐Herman, D., Kaufman, K. D., Amatruda, J. M., & Steinberg, H. O. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02589.x · Cited by 53
Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects
Drab, S. R. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.609 · Cited by 51
Mistry, G. C., Bergman, A. J., Zheng, W., Hreniuk, D., Zinny, M. A., Gottesdiener, K. M., Wagner, J. A., Herman, G. A., & Ruddy, M. K. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03148.x · Cited by 52
Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies
Meece, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167336 · Cited by 50
Metadata
- Authors
- Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group
- Affiliations
- Centre Hospitalier Universitaire de Nantes (FR)
- Sheba Medical Center (IL)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-12-01
- Volume
- 29
- Issue
- 12
- Pages
- 2638-2643
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2171512247
- Cited by
- 790
- References
- 12
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 19 · 2020: 19 · 2019: 15 · 2018: 12 · 2017: 27 · 2016: 29 · 2015: 39 · 2014: 47 · 2013: 48 · 2012: 47
- FWCI
- 60.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- sitagliptin, DPP-4 inhibitors, metformin, type 2 diabetes, inadequate glycemic control, HbA1c, pioglitazone, insulin sensitivity, beta-cell function, hypoglycemia, gastrointestinal adverse effects, body weight
- MeSH terms
- Sitagliptin Phosphate, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycoproteins, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Placebos, Proinsulin, Protease Inhibitors, Pyrazines, Triazoles, Single-Blind Method, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Adenosine Deaminase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.